Negative Trials, CAR T Studies Lead ASH Lymphoma Highlights
Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials. (Source: Medscape Oncology)
Source: Medscape Oncology - December 12, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Burden of Cancer Pain Worse in Some Countries
One of the greatest worries of a cancer patient is the possibility of a painful death. Unfortunately, a painless death is not something that many oncologists around the world are able to promise. (Source: Medscape Oncology)
Source: Medscape Oncology - November 17, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Two Ipilimumab Trials Show Survival Benefit, and More Toxicity
Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity. (Source: Medscape Oncology)
Source: Medscape Oncology - October 31, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Bonanza of New Options for HR+/HER2- Breast Cancer
Patients with advanced HR-positive/HER2-negative breast cancer may benefit from practice-changing treatment options, as reported by Dr Javier Cort é s from ESMO 2016. (Source: Medscape Oncology)
Source: Medscape Oncology - October 19, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Big News: Adjuvant Ipi Improves Survival in Melanoma
Dr Caroline Robert reviews melanoma highlights from ESMO 2016, focusing on results of ipilimumab in the adjuvant setting and the highest 3-year survival achieved in metastatic disease. (Source: Medscape Oncology)
Source: Medscape Oncology - October 17, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Is Immunotherapy Safe for Older Melanoma Patients?
How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients. (Source: Medscape Oncology)
Source: Medscape Oncology - September 22, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Biosimilars: Can They Be Trusted?
How similar are biosimilars to the index drug? Drs David Kerr and H å kan Mellstedt talk about how biosimilars are developed, regulated, and priced -- and whether they can be trusted by physicians. (Source: Medscape Oncology)
Source: Medscape Oncology - September 2, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Iconoclastic Breast Surgeon Laura Esserman Challenges the Status Quo
From screening to treatment, breast cancer specialist Laura Esserman is on a quest to individualize patient care, and in doing so she is challenging a number of long-standing practices in cancer care. (Source: Medscape Oncology)
Source: Medscape Oncology - August 8, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
